Barclays’s PharMerica Corporation PMC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-68,386
| Closed | -$2M | – | 7314 |
|
|
2017
Q3 | $2M | Buy |
68,386
+43,694
| +177% | +$1.22M | ﹤0.01% | 2365 |
|
|
2017
Q2 | $649K | Sell |
24,692
-8,148
| -25% | -$200K | ﹤0.01% | 3266 |
|
|
2017
Q1 | $768K | Sell |
32,840
-46,492
| -59% | -$1.15M | ﹤0.01% | 2972 |
|
|
2016
Q4 | $2M | Buy |
79,332
+30,929
| +64% | +$781K | ﹤0.01% | 2123 |
|
|
2016
Q3 | $1.36M | Buy |
48,403
+35,160
| +265% | +$901K | ﹤0.01% | 2340 |
|
|
2016
Q2 | $327K | Sell |
13,243
-46,382
| -78% | -$1.15M | ﹤0.01% | 3559 |
|
|
2016
Q1 | $1.31M | Buy |
59,625
+55,425
| +1,320% | +$1.48M | ﹤0.01% | 2304 |
|
|
2015
Q4 | $147K | Buy |
4,200
+3,046
| +264% | +$95.4K | ﹤0.01% | 4145 |
|
|
2015
Q3 | $32K | Sell |
1,154
-4,369
| -79% | -$147K | ﹤0.01% | 5258 |
|
|
2015
Q2 | $182K | Buy |
5,523
+4,589
| +491% | +$141K | ﹤0.01% | 4206 |
|
|
2015
Q1 | $27K | Sell |
934
-1,575
| -63% | -$39.1K | ﹤0.01% | 5678 |
|
|
2014
Q4 | $50K | Buy |
2,509
+1,458
| +139% | +$34.6K | ﹤0.01% | 5728 |
|
|
2014
Q3 | $24K | Buy |
1,051
+522
| +99% | +$13.8K | ﹤0.01% | 6387 |
|
|
2014
Q2 | $14K | Sell |
529
-686
| -56% | -$19.1K | ﹤0.01% | 6683 |
|
|
2014
Q1 | $32K | Sell |
1,215
-33,434
| -96% | -$821K | ﹤0.01% | 6334 |
|
|
2013
Q4 | $728K | Buy |
34,649
+7,980
| +30% | +$145K | ﹤0.01% | 3725 |
|
|
2013
Q3 | $347K | Buy |
26,669
+948
| +4% | +$12.8K | ﹤0.01% | 4498 |
|
|
2013
Q2 | $356K | Buy |
+25,721
| New | +$365K | ﹤0.01% | 4603 |
|
Barclays's PMC Position: Q4 2017 in Review
Barclays sold out of PharMerica Corporation (PMC) in Q4 2017, closing a stake of 68,386 shares — an estimated $2M sold.
Barclays first reported a position in PMC in Q2 2013 and held it in 18 quarters. The position peaked at $2M in Q3 2017. 0 funds tracked by Wall St. Rank hold PMC as of Q4 2017.
- Barclays reported no remaining PharMerica Corporation position as of Q4 2017 after selling out during the quarter.
- Barclays sold 68,386 PharMerica Corporation shares in Q4 2017, an estimated $2M.
- Barclays first reported a position in PharMerica Corporation in Q2 2013 and held it in 18 quarters.
- Barclays's PharMerica Corporation position peaked at $2M in Q3 2017.
- 0 funds tracked by Wall St. Rank held PharMerica Corporation as of Q4 2017.
Based on Barclays's 13F filing for Q4 2017, filed 14 Feb 2018.